跳至主導覽
跳至搜尋
跳過主要內容
排序方式
Keyphrases
Taiwan
100%
Lymphoma
100%
Biological Drugs
100%
Rheumatoid Arthritis Patients
100%
Tuberculosis
100%
Disease-modifying Therapy
100%
Serious Infection
100%
Serious Bacterial Infection
75%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
75%
Disease-modifying Antirheumatic Drugs (DMARDs)
62%
Etanercept
50%
Adalimumab
50%
Incidence Rate
37%
Propensity Score Matching
12%
Patient Characteristics
12%
Confidence Interval
12%
High Risk
12%
Exposure Time
12%
Time Rate
12%
Adult Patients
12%
Rheumatoid Arthritis
12%
Adverse Events
12%
Taiwan National Health Insurance Research Database
12%
Tuberculosis Diagnosis
12%
Capture Data
12%
Bacterial Infection Diagnosis
12%
Nursing and Health Professions
Bacterial Infection
100%
Infection
100%
Biological Product
100%
Rheumatoid Arthritis
100%
Disease Modifying Antirheumatic Drug
100%
Inflammatory Arthritis
100%
Diseases
100%
Adalimumab
66%
Etanercept
66%
Rate Ratio
50%
Propensity Score
16%
National Health Insurance
16%
Confidence Interval
16%
Adverse Event
16%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Bacterial Infection
100%
Rheumatoid Arthritis
100%
Biological Product
100%
Disease Modifying Antirheumatic Drug
100%
Inflammatory Arthritis
100%
Diseases
100%
Etanercept
66%
Adalimumab
66%
Adverse Event
16%
Retrospective Study
16%
Immunology and Microbiology
Inflammatory Arthritis
100%
Biological Product
100%
Disease-Modifying Antirheumatic Drug
100%
Adalimumab
66%
Etanercept
66%